Tag Archives: Tendering and procurement

Shanghai Opens TCM Procurement Alliance Listing for Fourth Batch

Leave a reply

Shanghai, Aug 31, 2026 — Shanghai’s Medical Procurement Center opened the online application channel for the fourth batch and second-batch renewal of the National Traditional Chinese Medicine Patent Medicines and Simple Preparations Purchasing Alliance centralized procurement, requiring selected manufacturers to complete platform registration by Sept 15, 2026.

Policy Snapshot

AttributeDetail
IssuerShanghai Medical Centralized Bidding and Procurement Affairs Management Center
DocumentNotice on Launching Application and Networking for Fourth and Second Batch Renewal of National TCM Patent Medicines Purchasing Alliance
BatchesZCYLM-2026-1 (Fourth Batch); ZCYLM-2026-2 (Second Batch Renewal)
Application windowAug 31, 2026 – Sept 15, 2026
PlatformShanghai Medical Procurement Association portal (www.smpaa.cn)
ModuleBusiness Operations → My Drug Library
Listing typeNon-national centralized procurement related drugs
Sub-typeNational alliance centralized procurement, renewal drugs (selected channel)

Key Provisions

  • Mandatory filing — All drugs on Shanghai’s supply list for the two batches must be registered; previously listed selected drugs are exempt from re-application.
  • Digital workflow — Enterprises log into the procurement subsystem via the SMPAA portal, navigate to the drug library module, and select the designated listing categories to submit product information.
  • Supply lists — Two annexes detail the selected varieties: the fourth batch (ZCYLM-2026-1) and the second-batch renewal (ZCYLM-2026-2).

Market Impact Analysis

The 16-day application window creates a tight compliance timeline for TCM manufacturers seeking to maintain Shanghai market access under the national alliance procurement framework. By routing the fourth batch and renewal products through a dedicated “selected channel” within the non-national centralized procurement category, regulators are preserving the distinction between national volume-based procurement and alliance-level TCM procurement while streamlining the local listing process.

For pharmaceutical companies, failure to register by the Sept 15 deadline risks exclusion from Shanghai’s public hospital and community health center formularies, a significant volume channel in one of China’s wealthiest healthcare markets. The exemption for already-listed products reduces administrative duplication but requires manufacturers to verify their current platform status against the new supply lists.

Forward-Looking Statement

Industry analysts expect Shanghai’s listing template to be replicated across other alliance member provinces in September, as the national TCM procurement alliance synchronizes local platform onboarding ahead of the fourth-quarter procurement cycle. The second-batch renewal mechanism suggests the alliance is transitioning toward a rolling contract model for mature TCM products, potentially reducing annual re-tendering friction. Companies with selected TCM formulations should prioritize the Shanghai digital registration workflow, as delays in the initial listing phase could cascade into missed procurement windows across the alliance network. Final supply list confirmations are anticipated by late September 2026.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/08/31/24240.shtml

Guangdong Adds Medical Consumables to Bargaining Procurement Platform

Leave a reply

Guangzhou, Aug 29, 2026 — Guangdong Province Drug Exchange Center published the first batch of newly added bargaining medical consumables for August 2026, expanding the provincial third-party drug electronic trading platform catalog and allowing healthcare institutions to negotiate purchases at or below listed prices.

Policy Snapshot

AttributeDetail
IssuerGuangdong Province Drug Exchange Center
DocumentNotice on Publishing Newly Added Bargaining Products for Medical Consumables (First Batch, August 2026)
PlatformGuangdong Province Third-Party Drug Electronic Trading Platform
ScopeMedical consumables with price confirmation submitted by July 27, 2026 (excluding medical insurance-managed consumables)
Pricing mechanismBargaining procurement at or below listed prices
Batch codeYJHCGW38-20260801
Effective dateAug 29, 2026

Key Provisions

  • Automatic listing — Products with confirmed price information and completed listing applications submitted before July 27, 2026, that received no objections during the public notice period are formally added to the bargaining procurement catalog.
  • Pricing ceiling — Healthcare institutions must negotiate purchases at prices not exceeding the published listed prices.
  • Deferred listings — Products with pending information verification or incomplete registration certificate status will be listed after administrative resolution.

Market Impact Analysis

The batch release reflects Guangdong’s continued expansion of its centralized medical consumables procurement framework, shifting more products toward negotiated pricing models. By excluding medical insurance-managed consumables from this round, regulators are targeting elective or non-reimbursable devices and supplies where market-based bargaining can drive cost efficiencies without disrupting national reimbursement protocols.

For manufacturers, inclusion in the bargaining catalog provides formal access to Guangdong’s vast public hospital network but caps pricing autonomy, requiring careful negotiation strategies to balance volume commitments against margin preservation. The automated confirmation workflow—where enterprises verify price information through the platform’s digital interface—reduces administrative friction but demands real-time monitoring of registration status to avoid listing delays.

Forward-Looking Statement

Industry analysts expect Guangdong to maintain a monthly or biweekly cadence for new bargaining consumables batches through year-end, as the province transitions toward fuller catalog coverage under the third-party platform. The explicit exclusion of medical insurance-managed items suggests a parallel regulatory track for high-value reimbursed devices, where stricter price ceilings may be imposed separately. Companies seeking Guangdong market access should prioritize platform registration and price confirmation workflows, as the automatic listing mechanism rewards prompt compliance while penalizing documentation gaps with delayed commercialization timelines.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2093659765451264000

Qinghai Adds Flu Vaccines to Non-Immunization Procurement List

Leave a reply

Xining, Aug 25, 2026 — Qinghai Province’s Center for Disease Control and Prevention released the second batch of expert demonstration results for its 2026 non-immunization vaccine procurement expansion, clearing three influenza vaccine products for online platform listing after a July 8 expert review session.

Procurement Roster

No.Generic NameDosage FormSpecificationPackagingManufacturerApplicantPrice (CNY)
1Influenza Virus Split VaccineInjection0.5 ml/vialVialHualan Biological Vaccine Inc.Hualan Biological Vaccine Inc.78.00
2Influenza Virus Split VaccineInjection0.25 ml/dosePre-filled SyringeHualan Biological Vaccine Inc.Hualan Biological Vaccine Inc.68.00
3Influenza Virus Subunit VaccineInjection0.5 ml/dosePre-filled SyringeZhongyi Anke Biotechnology Co., Ltd.Zhongyi Anke Biotechnology Co., Ltd.268.00

Regulatory Context

The results follow Qinghai CDC Bureau [2025] No. 39, the provincial implementation plan for centralized online procurement of non-immunization vaccines. The review process encompassed enterprise application, documentation screening, on-site price negotiation, and expert panel certification. All three products were deemed compliant after supplementary materials were submitted. The public comment window runs from Aug 25 to Sept 1, 2026.

Market Impact Analysis

The inclusion of two Hualan Biological split-virus influenza vaccines and one Zhongyi Anke subunit formulation expands Qinghai’s elective flu vaccine portfolio ahead of the autumn immunization season. Hualan’s dual-format offering—vial and pre-filled syringe at 78 yuan and 68 yuan respectively—targets different age groups and procurement budgets, while Zhongyi Anke’s premium subunit vaccine at 268 yuan positions itself as a high-efficacy alternative in a province where vaccine access has historically been constrained by logistics and cold-chain infrastructure.

The 68-yuan to 268-yuan price spread reflects a tiered market strategy, allowing public health facilities to match vaccine selection to patient affordability and clinical indication. For manufacturers, securing slots on Qinghai’s non-immunization procurement platform guarantees formulary access across the province’s public vaccination network, a critical channel in a region with limited private clinic penetration.

Forward-Looking Statement

Industry analysts expect the three products to clear the one-week public comment period without material objections, enabling formal platform listing before the peak flu vaccination window opens in October. The July expert review and August publication timeline suggest Qinghai is front-loading its non-immunization vaccine procurement calendar, potentially signaling earlier-than-usual provincial tendering cycles for 2026. Hualan Biological’s dominant position in this batch—two of three slots—reinforces its standing in China’s seasonal flu vaccine market, while Zhongyi Anke’s subunit entry at a 3.4x price premium tests demand elasticity for advanced influenza formulations in western China.-China Health Reform Pulse

Policy Source: https://www.qhcdc.org.cn/xwzx/tzgg/content_3900